Immutep Outcome from DSMB Safety Review and Extension of TACTI-mel Phase I Clinical Trial Genetics Investing
Pacific Biosciences Announces Outcome of First Phase of Patent Litigation Against Oxford Nanopore Genetics Investing
Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing Biotech Investing
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update Biotech Investing
Adverum Biotechnologies Announces Pricing of $60 Million Public Offering of Common Stock Biotech Investing
